Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

BioNTech: Clinical Trials & FDA Approval Profile

BioNTech (Mainz, DE / Cambridge, MA) sponsors 58 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 25 active protocols (19 recruiting now), 26 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)12.1%
Median Closed Enrollment vs National (145 pts)629 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for BioNTech
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)58
Active Pipeline (Recruiting Now)25 (19)
Completed vs Stopped Early26 / 7 (12.1%)
Median Closed Actual Enrollment629 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With BioNTech
Hospital Research SiteLocationShared Protocols
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CT11

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by BioNTech
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07173751ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerPhase IIIRECRUITING
NCT06340568A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerPhase IIIRECRUITING
NCT06841055Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in CombinatioPhase IIRECRUITING
NCT06712316Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTAPhase II/IIIRECRUITING
NCT07255404A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for PeoplePhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the BioNTech Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI